title: Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?
authors.affiliation: Hippokration General Hospital, Thessaloniki, Greece.
authors.forename: Spyros
authors.initials: S
authors.lastname: Aslanidis
authors.forename: Athina
authors.initials: A
authors.lastname: Pyrpasopoulou
authors.forename: Stella
authors.initials: S
authors.lastname: Douma
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Petidis
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014397:Tuberculosis, Pulmonary / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab